We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

4 Firms Spearhead $1.2B Catalent-Paragon Bioservices Deal

Law360 (April 15, 2019, 2:15 PM EDT) -- Drug development and delivery company Catalent on Monday agreed to buy private equity-backed Paragon Bioservices Inc. for $1.2 billion, in a deal steered by Fried Frank, Kirkland, Gordon Feinblatt and Latham....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.